Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Immunogenicity and safety of H1N1 influenza hemagglutinin protein expressed in a baculovirus system.

Na HN, Kim KH, Song MK, Park HL, Lee EY, Shim SH, Park S, Nam JH.

Microbiol Immunol. 2013 Sep;57(9):660-4. doi: 10.1111/1348-0421.12079.

2.

Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.

Musthaq SK, Kumar SR, Szyporta M, Kwang J.

Antiviral Res. 2014 Sep;109:42-53. doi: 10.1016/j.antiviral.2014.06.002. Epub 2014 Jun 25.

PMID:
24973759
3.

Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.

Rajesh Kumar S, Syed Khader SM, Kiener TK, Szyporta M, Kwang J.

PLoS One. 2013 Jun 7;8(6):e63856. doi: 10.1371/journal.pone.0063856. Print 2013.

4.

Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.

Prabakaran M, Meng T, He F, Yunrui T, Qiang J, Lin RT, Kwang J.

Clin Vaccine Immunol. 2011 Sep;18(9):1582-5. doi: 10.1128/CVI.05114-11. Epub 2011 Jul 13.

5.

Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines.

Sun X, Cao W, Pappas C, Liu F, Katz JM, Tumpey TM.

Virology. 2014 Sep;464-465:156-65. doi: 10.1016/j.virol.2014.07.004. Epub 2014 Jul 30.

6.

Insect larvae biofactories as a platform for influenza vaccine production.

Gomez-Casado E, Gomez-Sebastian S, Núñez MC, Lasa-Covarrubias R, Martínez-Pulgarín S, Escribano JM.

Protein Expr Purif. 2011 Sep;79(1):35-43. doi: 10.1016/j.pep.2011.03.007. Epub 2011 Mar 21.

PMID:
21421054
7.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.

Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27.

PMID:
19716456
8.

Protection of mice against pandemic H1N1 influenza virus challenge after immunization with baculovirus-expressed stabilizing peptide fusion hemagglutinin protein.

Yang E, Cho Y, Choi JA, Choi Y, Park PG, Park E, Lee CH, Lee H, Kim J, Lee JM, Song M.

J Microbiol Biotechnol. 2015 Feb;25(2):280-7.

9.

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM.

J Infect Dis. 2006 May 1;193(9):1223-8. Epub 2006 Mar 28.

PMID:
16586358
10.

Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice.

Athmaram TN, Saraswat S, Santhosh SR, Singh AK, Suryanarayana WS, Priya R, Gopalan N, Parida M, Rao PV, Vijayaraghavan R.

Virol J. 2011 Nov 29;8:524. doi: 10.1186/1743-422X-8-524.

11.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
12.

[Expression of Chimeric Influenza Hemagglutinin Antigen (cH7/3) using the Baculovirus Expression System and Identification of its Biological Activities].

Wang D, Qin K, Guo J, Zhao X, Lu S, Shu Y, Zhou J.

Bing Du Xue Bao. 2015 Sep;31(5):524-9. Chinese.

PMID:
26738290
13.

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.

Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, Kushnir N, Sharma S, Yusibov V.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:41-50. Epub 2011 Jan 1.

PMID:
21266846
14.

Baculovirus vector as an avian influenza vaccine: hemagglutinin expression and presentation augment the vaccine immunogenicity.

Chen CY, Lin SY, Cheng MC, Tsai CP, Hung CL, Lo KW, Hwang Y, Hu YC.

J Biotechnol. 2013 Mar 10;164(1):143-50. doi: 10.1016/j.jbiotec.2012.12.013. Epub 2013 Jan 10.

PMID:
23313887
15.

Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian 'avian-like' H1N1 swine viruses in mice.

Castrucci MR, Facchini M, Di Mario G, Garulli B, Sciaraffia E, Meola M, Fabiani C, De Marco MA, Cordioli P, Siccardi A, Kawaoka Y, Donatelli I.

Influenza Other Respir Viruses. 2014 May;8(3):367-75. doi: 10.1111/irv.12221. Epub 2013 Dec 23.

16.

Influenza virus vaccines: lessons from the 2009 H1N1 pandemic.

Broadbent AJ, Subbarao K.

Curr Opin Virol. 2011 Oct;1(4):254-62. doi: 10.1016/j.coviro.2011.08.002. Review.

17.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM.

Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28.

PMID:
21277410
18.

Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice.

Fang J, Chen Z, Liu X, Li H, Wang J, Shen X, Chen W, Liu Y, Wang Y, Zhao P, Qi Z.

J Virol Methods. 2011 May;173(2):314-9. doi: 10.1016/j.jviromet.2011.03.001. Epub 2011 Mar 12.

PMID:
21392537
20.

Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, García-Sastre A, Albrecht RA.

J Virol. 2014 Mar;88(6):3432-42. doi: 10.1128/JVI.03004-13. Epub 2014 Jan 8.

Supplemental Content

Support Center